An early-stage venture capital investor is focused on globally scalable technology companies with connections to Southeast Asia and the United States. The firm primarily invests at the Pre-Seed, Seed, and Pre-Series A stages, typically deploying approximately $150K–$1M per company and generally targeting ownership positions of 5–15%. A meaningful portion of the firm’s capital is allocated to life sciences and healthcare innovation. The firm leverages technical expertise, entrepreneurial experience, and international operating networks to support early-stage companies pursuing global growth.
Within life sciences and healthcare, the firm focuses on techbio and technology-enabled healthcare innovation. Areas of interest include computational biology, artificial intelligence and machine learning, protein and RNA technologies, gene editing and CRISPR, precision therapeutics, AI-enabled drug discovery, biomaterials, regenerative medicine, tissue engineering, synthetic biology, screening and diagnostics, digital health, healthcare analytics, and health data infrastructure. The firm is comfortable investing at very early stages, including preclinical and research-stage opportunities, and is generally indication-agnostic, with additional interest in neurotechnology and neuroscience.
From a company and management team perspective, the firm seeks ambitious founders and technically strong teams developing differentiated intellectual property and defensible technology platforms. The firm can lead or co-invest and generally seeks board participation when leading a financing. The firm actively supports portfolio companies with technology strategy, business scaling, international expansion, recruiting, and future fundraising through its network of operators, technologists, and industry experts.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 